20:12 Mon 19 Oct 2020
Ergomed plc - Result of General Meeting
Ergomed Plc
Result of General Meeting
The Capital Reduction remains subject to the Court's approval and a directions hearing is scheduled for
A further announcement will be made following the Capital Reduction becoming effective.
Terms used but not defined in this announcement are as defined in the Company's announcement of
Details of the voting in respect of each resolution are shown in the table below:
|
For |
Against |
Withheld |
||
Resolution |
No. of Shares |
% |
No. of Shares |
% |
No. of Shares |
1. To cancel the Company's Share Premium Account |
41,339,888 |
100 |
2,000 |
0 |
1,414 |
2. To capitalise the Company's Merger Reserve by paying up B Shares |
41,339,888 |
100 |
Nil |
0 |
3,414 |
3. To cancel the B Shares |
41,339,888 |
100 |
Nil |
0 |
3,414 |
Notes:
1. Votes "For" and "Against" are expressed as a percentage of votes received.
2. A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.
3. Percentages in relation to Resolution 1 are rounded.
ENDS
Enquiries:
Ergomed plc |
Tel: +44 (0) 1483 402 975 |
Miroslav Reljanović (Executive Chairman) |
|
|
|
|
|
Numis Securities Limited |
Tel: +44 (0) 20 7260 1000 |
|
|
|
|
|
|
Consilium Strategic Communications - for |
Tel: +44 (0) 20 3709 5700 |
|
|
|
|
|
|
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE